ConductScience.org, home

Paper40940901

Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance.

Leite LF and 9 others. Cancers (Basel), 2025. Cited by 26 papers, by iCite.

Cite this record

ConductScience Library. Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance. Papers, record 40940901. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40940901

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance.
PubMed
Journal
Cancers (Basel)
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
26
iCite
Relative citation ratio, by iCite
6.86, provisional
iCite
Revised in PubMed
2025-09-16
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Leite LFLuís Felipe
2Noronha MMMariana Macambirahttps://orcid.org/0000-0003-0889-7425
3de Menezes JSAJunior Samuel Alonso
4da Conceição LDLucas Diniz
5Almeida LFCLuiz F Costahttps://orcid.org/0009-0008-3286-3333
6Cappellaro APAnelise Poluboiarinovhttps://orcid.org/0009-0001-1624-7556
7Belotto MMarcos
8Biachi de Castria TTiagohttps://orcid.org/0000-0001-6832-2485
9Peixoto RDRenata D'Alpinohttps://orcid.org/0000-0003-0053-7951
10Megid TBCThais Baccili Cury

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References157

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
120088793Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.Curr Cancer Drug Targets2010https://conductscience.org/library/papers/20088793PubMed
218392055Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias.Br J Cancer2008https://conductscience.org/library/papers/18392055PubMed
337243489Targeting the EGFR signaling pathway in cancer therapy: What's new in 2023?Expert Opin Ther Targets2023https://conductscience.org/library/papers/37243489PubMed
427907852The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.Eur J Cancer2017https://conductscience.org/library/papers/27907852PubMed
521900593Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.Sci Transl Med2011https://conductscience.org/library/papers/21900593PubMed
632988996Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial.ESMO Open2020https://conductscience.org/library/papers/32988996PubMed
738473821Gluing GAP to RAS Mutants: A New Approach to an Old Problem in Cancer Drug Development.Int J Mol Sci2024https://conductscience.org/library/papers/38473821PubMed
837774394Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer.Oncologist2023https://conductscience.org/library/papers/37774394PubMed
937463037Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes.Oncologist2023https://conductscience.org/library/papers/37463037PubMed
1037071094Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.JAMA2023https://conductscience.org/library/papers/37071094PubMed
1134830853Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors.Cancers (Basel)2021https://conductscience.org/library/papers/34830853PubMed
1227865140Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR.Cancer Treat Rev2016https://conductscience.org/library/papers/27865140PubMed
1336419886Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer.Front Oncol2022https://conductscience.org/library/papers/36419886PubMed
1438711991Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road.Front Pharmacol2024https://conductscience.org/library/papers/38711991PubMed
1518339877PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.Cancer Res2008https://conductscience.org/library/papers/18339877PubMed
1639693606Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer.Cancer Res2025https://conductscience.org/library/papers/39693606PubMed
1718223225Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies.Clin Cancer Res2008https://conductscience.org/library/papers/18223225PubMed
1836702949Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial.Nat Med2023https://conductscience.org/library/papers/36702949PubMed
1935427766EGFR signaling pathway as therapeutic target in human cancers.Semin Cancer Biol2022https://conductscience.org/library/papers/35427766PubMed
2027345413FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling.Oncogene2017https://conductscience.org/library/papers/27345413PubMed

See all 157 referencesDownload CSV of references

Cited by27

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.

PMIDTitleJournalYearIn PapersSource
42938848An Exploratory Study of ABT-806, a Tumor-Specific Anti-EGFR Antibody, in Subjects with Recurrent or Metastatic Head and Neck and Other Squamous Cell Carcinomas.Cancers (Basel)2026https://conductscience.org/library/papers/42938848PubMed
42828116Colorectal Cancer: Epidemiology, Risk Factors, Signaling Pathways, Clinical Features, Screening, Diagnosis, and Management.MedComm (2020)2026https://conductscience.org/library/papers/42828116PubMed
42738319PIK3CA in Cancer: Structure, Biology, Alterations, and Actionability.Cancers (Basel)2026https://conductscience.org/library/papers/42738319PubMed
42649986Biological and Targeted Therapies in the Multidisciplinary Management of Gastrointestinal Cancers.Cancers (Basel)2026https://conductscience.org/library/papers/42649986PubMed
42635595EMB-01, an Anti-EGFR/c-MET Bispecific Antibody, in Patients with Heavily Pretreated Metastatic Colorectal Cancer from a Phase Ib/II, Open-Label, Multicenter Study.Clin Cancer Res2026https://conductscience.org/library/papers/42635595PubMed
42588741The Genetic Landscape of Colorectal Cancer: From Molecular Alterations to Therapeutic Decision Pathways.Cancers (Basel)2026https://conductscience.org/library/papers/42588741PubMed
42588722Targeting β-Adrenergic Signaling in Colorectal Cancer: Molecular Mechanisms and Therapeutic Potential of β-Blockers.Cancers (Basel)2026https://conductscience.org/library/papers/42588722PubMed
42515723Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/42515723PubMed
42511923Enhancing Targeted Colorectal Cancer Therapies with Natural Products: Mechanistic Pathways.Biomedicines2026https://conductscience.org/library/papers/42511923PubMed
42240876Who Truly Benefits from Anti-EGFR Rechallenge in Metastatic Colorectal Cancer? From Clinical Enrichment to ctDNA-Guided Molecular Hyperselection.J Gastrointest Cancer2026https://conductscience.org/library/papers/42240876PubMed
42147347Common oncogenic mutations in colorectal cancer: drivers of carcinogenesis and potential therapeutic targets.Front Pharmacol2026https://conductscience.org/library/papers/42147347PubMed
42123533Liquid Biopsy in Colorectal Cancer: Future Perspectives Through the Lens of Artificial Intelligence-A Comprehensive Review of Novel Literature.Int J Mol Sci2026https://conductscience.org/library/papers/42123533PubMed
42074578Genomic Landscape, Targeted Therapies, and Mechanisms of Resistance in Molecularly Selected Metastatic Colorectal Cancer Patients.Genes (Basel)2026https://conductscience.org/library/papers/42074578PubMed
42022325Precision oncology in gynecologic cancers: molecular taxonomy, biomarker-guided therapeutics, and the challenge of therapeutic resistance.Front Oncol2026https://conductscience.org/library/papers/42022325PubMed
41977448EGFR Signaling in Colorectal Cancer: Novel Therapeutic Strategies, Predictive Biomarkers, and Counteracting Treatment Resistance.Int J Mol Sci2026https://conductscience.org/library/papers/41977448PubMed
41959919Risk of high-grade infections in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a meta-analysis of randomized controlled trials.Front Oncol2026https://conductscience.org/library/papers/41959919PubMed
41756334Clinical trials of bispecific antibody therapy for colorectal cancer: advanced and next steps.Front Oncol2026https://conductscience.org/library/papers/41756334PubMed
41742069ERBITAG: Non-interventional study on the efficacy of cetuximab in first-line therapy in patients with RAS wild-type metastatic colorectal cancer.BMC Cancer2026https://conductscience.org/library/papers/41742069PubMed
41670652Beyond the membrane: rethinking EGFR signaling in physiology and cancer.Cell Mol Life Sci2026https://conductscience.org/library/papers/41670652PubMed
41590540Comprehensive Landscape of Diagnostic, Prognostic and Predictive Biomarkers in Colorectal Cancer: From Genomics to Multi-Omics Integration in Precision Medicine.J Pers Med2026https://conductscience.org/library/papers/41590540PubMed

See all 27 cited byDownload CSV of cited by

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
BRAF673PubTator's text mininghttps://conductscience.org/library/genes/673NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
PIK3CB5291PubTator's text mininghttps://conductscience.org/library/genes/5291NCBI Gene
SLTM79811PubTator's text mininghttps://conductscience.org/library/genes/79811NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40940901

GET https://conductscience.org/api/papers/v1/40940901/references?page=2